TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients
暂无分享,去创建一个
J. Foekens | J. Klijn | M. Look | E. Berns | M. Smid | I. L. van Staveren | W. van Putten
[1] L. Holmberg,et al. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy , 1995, Nature Medicine.
[2] E. Hovig,et al. TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc‐binding domains , 1995, Genes, chromosomes & cancer.
[3] J. Foekens,et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. , 1995, Gene.
[4] L. Norton,et al. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] D. Thorley-Lawson,et al. A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.
[6] J. Cunningham,et al. p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. , 1995, Oncogene.
[7] J. Eyfjörd,et al. p53 abnormalities and genomic instability in primary human breast carcinomas. , 1995, Cancer research.
[8] John Calvin Reed,et al. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.
[9] P. O'Connor,et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. , 1994, Science.
[10] D. Housman,et al. p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.
[11] C. Harris,et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.
[12] C. Prives. How loops, β sheets, and α helices help us to understand p53 , 1994, Cell.
[13] N F Cariello,et al. Database and software for the analysis of mutations in the human p53 gene. , 1994, Cancer research.
[14] S. Friend. p53: a glimpse at the puppet behind the shadow play. , 1994, Science.
[15] P. Jeffrey,et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.
[16] G. Hannon,et al. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA , 1994, Nature.
[17] M. Oren. Relationship of p53 to the control of apoptotic cell death. , 1994, Seminars in cancer biology.
[18] W. Dupont,et al. P53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment , 1994, Cancer.
[19] C. Croce,et al. Down-regulation of bcl-2 by p53 in breast cancer cells. , 1994, Cancer research.
[20] N. Weidner,et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] David Beach,et al. p21 is a universal inhibitor of cyclin kinases , 1993, Nature.
[22] S. Elledge,et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.
[23] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.
[24] K. Heimdal,et al. Prognostic significance of TP53 alterations in breast carcinoma. , 1993, British Journal of Cancer.
[25] G. Merlo,et al. In primary human breast carcinomas mutations in exons 5 and 6 of the p53 gene are associated with a high s‐phase index , 1993, International journal of cancer.
[26] J. Foekens,et al. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Scott W. Lowe,et al. p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.
[28] Leland Hartwell,et al. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells , 1992, Cell.
[29] Thea D. Tlsty,et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.
[30] A. Levine,et al. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[31] C. Theillet,et al. p53 mutations occur in aggressive breast cancer. , 1992, Cancer research.
[32] J. Bartek,et al. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. , 1992, Journal of immunological methods.
[33] E. Kawasaki,et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.
[34] J. Marks,et al. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[35] J. Foekens,et al. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. , 1992, Cancer research.
[36] S. Sukumar,et al. Mutations in p53 as potential molecular markers for human breast cancer. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[37] D. Carbone,et al. Polymorphism at codon 213 within the p53 gene. , 1991, Oncogene.
[38] J. Bartek,et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. , 1991, Oncogene.
[39] B. Vogelstein,et al. p53 mutations in human cancers. , 1991, Science.
[40] A. Levine,et al. The p53 tumour suppressor gene , 1991, Nature.
[41] H. J. Evans,et al. Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours. , 1990, Oncogene.
[42] J. Foekens,et al. Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. , 1989, Cancer research.
[43] T. Sekiya,et al. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. , 1989, Genomics.
[44] T. Sekiya,et al. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[45] T. Shows,et al. Transformation associated p53 protein is encoded by a gene on human chromosome 17 , 1985, Somatic cell and molecular genetics.
[46] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[47] A. Harris. p53 expression in human breast cancer. , 1992, Advances in cancer research.